Summary of T 439/22 This decision represents a further development of the earlier T 439/22 proceedings, which led to the G1/24 referral to the EPO’s Enlarged Board of Appeal (EBA). The decision of the EBA was reported in our previous article. To recap, granted claim 1...
Background: PGR and IPR Patent offices around the world strive to grant valid patents, but sometimes cases slip through the net and proceed to grant when they shouldn’t have. For this reason, many patent offices provide mechanisms for third parties to challenge their...
Background REGENXBIO and the Trustees of the University of Pennsylvania sued Sarepta for infringing multiple claims of U.S. Patent No. 10,526,617, which is directed to cultured host cells containing a recombinant nucleic acid molecule encoding an AAV capsid sequence...
This case is important because it allows the Supreme Court to define the point of balance between enforcement of patent rights for medical uses and the competition in the market place for generic pharmaceuticals. Consequently, the ruling of the Supreme Court will have...
To be patentable in the UK, an invention must meet a patent eligibility requirement. Some inventions — including business methods and computer programs “as such” — are ineligible even if the invention is otherwise novel and inventive. For many years, UK eligibility...
Recent Comments